Key result
Aspirin use following a diagnosis of breast cancer was associated with a significantly lower risk of all-cause mortality (HR 0.53) compared to non-use.
Why the study?
Does aspirin use postdiagnosis reduce mortality in women with breast cancer?
Population
4,627 women diagnosed with breast cancer between 1 January 1998 and 31 December 2008 in Tayside, Scotland…
Comparison
Aspirin prescribed postdiagnosis vs No aspirin prescribed postdiagnosis
Design
Cohort
Follow-up
Followed up until 28 February 2010
Authors
Loading...
Potential survival benefit with post-diagnosis aspirin; leaves open need for randomized confirmation before practice change.
Cohort (n=4,627)
Does aspirin use postdiagnosis reduce mortality in women with breast cancer?
Hazard Ratio: 0.53 (95% CI 0.45–0.63)
p-value: p=<0.001
Aspirin use after breast cancer diagnosis is associated with significantly reduced all-cause and breast cancer-specific mortality.
Fraser et al. (2014) conducted a cohort in Breast cancer (n=4,627). Aspirin vs. No aspirin use postdiagnosis was evaluated on All-cause mortality (HR 0.53, 95% CI 0.45-0.63, p=<0.001). Aspirin use following a diagnosis of breast cancer was associated with a significantly lower risk of all-cause mortality (HR 0.53) compared to non-use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: